(Bio)chemical Strategies To Modulate Amyloid-β Self-Assembly

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Alzheimer's disease (AD) is characterized by amyloid plaques, formed by self-assembled amyloid-β (Aβ) peptides.
• Aβ peptides are generated from the amyloid precursor protein and their soluble aggregates are toxic to neurons.
• Modulating Aβ self-assembly is a key research area for AD therapeutic development.

Purpose of the Study:

• To provide an overview of the mechanistic ways to modulate Aβ aggregation.
• To identify the specific steps in Aβ self-assembly that aggregation modulators can interfere with.
• To categorize Aβ aggregation modulators based on key parameters.

Main Methods:

• Review and synthesis of existing literature on Aβ aggregation modulators.
• Classification of modulators based on interaction type (weak, coordination, covalent).
• Analysis of modulator effects considering kinetics, thermodynamics, molecular size, and binding specificity.

Main Results:

• Various chemical and biological molecules can modify Aβ aggregation.
• Modulators can interfere at different stages of the Aβ self-assembly process.
• Key parameters influencing modulator efficacy include interaction type, kinetics, thermodynamics, size, and specificity.

Conclusions:

• Understanding the diverse mechanisms of Aβ aggregation modulation is essential for designing effective AD therapies.
• Targeting specific steps or interactions in Aβ self-assembly offers potential therapeutic strategies.
• A comprehensive approach considering various modulator properties is needed for successful intervention.